Comparison. Research use only.
BPC-157 vs GHK-Cu
BPC-157 and GHK-Cu are the two most-cited research peptides in tissue and skin recovery models. They work through different mechanisms: BPC-157 modulates growth factor pathways across multiple tissue types, while GHK-Cu acts as a copper chaperone influencing collagen synthesis and gene expression.
What is the difference between BPC-157 and GHK-Cu?
BPC-157 is a synthetic 15-amino-acid peptide taken from a human gastric protein sequence and studied for growth factor (VEGFR2) and nitric oxide signalling. GHK-Cu is a naturally occurring copper-binding tripeptide that acts as a copper chaperone for collagen-related enzymes. Their evidence differs too: BPC-157 data are entirely preclinical, while GHK-Cu also has topical cosmetic studies in humans.
| Attribute | BPC-157 | GHK-Cu |
|---|---|---|
| Molecule class | Synthetic pentadecapeptide (15 amino acids) | Naturally occurring tripeptide-copper(II) complex (Gly-His-Lys · Cu) |
| Molecular weight | 1419.53 Da | 403.93 Da |
| Origin | Conserved sequence from the human gastric juice protein BPC | First isolated from human plasma albumin (Pickart and Thaler, 1973) |
| Proposed mechanism | VEGFR2 upregulation, nitric oxide modulation, FAK-paxillin activation; receptor not identified | Copper delivery to lysyl oxidase, SOD1 and cytochrome c oxidase; collagen I, III and VI synthesis in fibroblasts |
| Human evidence | No completed human clinical trials published | Topical cosmetic double-blind study (Leyden et al., 2005, n=67) |
| Typical research models | Rat Achilles tendon, NSAID gastropathy and angiogenesis models | Dermal fibroblast culture, Connectivity Map gene-expression analysis, wound models |
| Regulatory / WADA | Investigational, no approved use; WADA S0 since 2023 | Used in topical cosmetics; not on the WADA prohibited list |
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a chain of 15 amino acids, taken from a conserved sequence within the human gastric juice protein BPC. It is unusually stable in gastric acid, plasma, and tissue (hence the name 'stable gastric pentadecapeptide'), which sets it apart from most endogenous peptides.
Read the full BPC-157 research summary →What is GHK-Cu?
GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring copper-binding tripeptide, first isolated from human plasma albumin by Pickart and Thaler in 1973. It is present at concentrations of ~200 ng/mL in plasma of young adults, and declines substantially with age.
Read the full GHK-Cu research summary →BPC-157 and GHK-Cu specifications
Frequently asked questions
Has BPC-157 or GHK-Cu been studied in humans?
No completed human clinical trials of BPC-157 have been published; its tendon, gastric and vascular findings come from rat and mouse models such as Staresinic et al. (2003). GHK-Cu has limited human data, all topical: a double-blind cosmetic study (Leyden et al., 2005, n=67) reported changes in skin elasticity. Neither BPC-157 nor GHK-Cu has an approved therapeutic indication, and both are supplied for research use only.
Do BPC-157 and GHK-Cu work through the same mechanism?
No. BPC-157's receptor has not been identified; preclinical work links it to VEGFR2 upregulation, nitric oxide synthase modulation and FAK-paxillin signalling. GHK-Cu's activity depends on its bound copper ion: the complex delivers copper to enzymes such as lysyl oxidase and superoxide dismutase, and in fibroblast culture it increased collagen I, III and VI synthesis (Pickart et al., 2015). Both appear in tissue-repair research, but through unrelated pathways.
Why are BPC-157 and GHK-Cu compared?
BPC-157 and GHK-Cu are the two most-cited peptides in tissue and skin recovery research, so they are frequently grouped together. The comparison is mostly about research context rather than mechanism: BPC-157 literature centres on tendon, gastric and vascular models in rodents, while GHK-Cu literature centres on dermal fibroblasts, extracellular matrix remodelling and topical cosmetic studies.
What is the regulatory status of BPC-157 and GHK-Cu?
BPC-157 is an investigational peptide with no approved use in any jurisdiction, and WADA added it to its S0 (Non-Approved Substances) list in 2023. GHK-Cu is widely used in topical cosmetic formulations, has no approved therapeutic indication outside cosmetics, and does not appear on the WADA prohibited list. Veridian supplies both BPC-157 and GHK-Cu strictly for laboratory research.
Other research peptide comparisons
Both compounds in stock at Veridian. 99%+ HPLC purity, same-day US shipping.
Browse all research peptides →